Key Highlights
- SELLAS turned lower on Wednesday after proposing a $150 million offering.
- The shares soared on Tuesday on clinical trial data.
- Companies often raise Capital after a big run-up in their share price.
- Health care was one of the weakest sectors on the day.
From rally to share sale
SELLAS Life Sciences (NASDAQ:SLS) turned lower on Wednesday, placing the stock among the decliners in the Russell 2000. The move came after the company proposed a $150 million share offering.
The offering followed a dramatic Tuesday. SELLAS shares soared that day on clinical trial data, and companies often move to raise capital after a big run-up in their share price.
Wednesday's trading was choppy. The stock was modestly higher in late morning but later turned lower.
Why companies raise money after a rally
For a clinical-stage biotech, a jump in the share price creates an opportunity. Selling stock at a higher price means the company can raise more cash while issuing fewer new shares. That cash can fund trials, regulatory work and operations for longer, reducing the need to return to the market soon.
The flip side is dilution. New shares mean each existing share represents a smaller slice of the company, and offerings are usually priced at a discount to attract buyers. That is why stocks often give back some gains when an offering is announced, even when the underlying news that drove the rally remains positive.
The final size, price and timing of the offering will be set at pricing.
What SELLAS does
SELLAS Life Sciences is a late-stage biopharmaceutical company developing cancer therapies. Like other clinical-stage drug developers, it does not yet rely on product sales, so its value depends on trial results, regulatory decisions and its ability to fund development. Those factors can make its shares swing sharply on news.
A rough day for health care
The broader health care sector was weak. Health care was the second-worst performer in the S&P 500 on Wednesday, behind only energy. Health insurers led the slide after the Centers for Medicare and Medicaid Services proposed expanding Medicare Advantage audits, with UnitedHealth Group (NYSE:UNH) the worst performer in the Dow and Humana (NYSE:HUM) the worst in the S&P 500. Large drugmakers including Merck (NYSE:MRK) and Eli Lilly (NYSE:LLY) also slipped. Clinical-stage biotech companies have little direct exposure to that rule.
The major indexes were mixed. The S&P 500 slipped 16.90 points to 7,323.63, its fifth straight loss and its longest losing streak since June. The Dow fell 561.25 points to 50,198.17, while the Nasdaq Composite rose 101.50 points to 24,429.88 and the Russell 2000 gained 12.44 points to 2,714.31.
Minutes from the Federal Reserve's October meeting showed almost all participants judged that further increases in the federal funds rate "would likely be appropriate." Higher rates can weigh on biotech valuations, which depend on profits expected years in the future.
Fresh Capital Raises Questions After SELLAS' Trial-Data Surge
The next milestone is the pricing of the offering, which will show how much the company raises, at what price and how many new shares it issues. Investors will also look for further details on the trial data that drove Tuesday's rally and on the company's development and regulatory timeline.
On the macro calendar, Thursday brings weekly jobless claims, the Philadelphia Fed survey and Walmart (NASDAQ:WMT) Earnings before the open. The Fed's next policy meeting is December 8 and 9.

_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)



Please wait processing your request...